CRISPR Therapeutics AG - Common Shares (CRSP)
$44.51
2.06 (4.42%)
CRSP Stock Quote Delayed 30 Minutes
7 Biotech Stocks to Buy for Their Game-Changing Potential
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
3.51B
PE Ratio
-10.23
EPS
-4.35
Volume (Avg. Vol.)
2.16M
Day's Range
$44.02 - $46.67
52-Week Range
$36.52 - $90.62
Dividend & Yield
N/A (N/A)
CRSP Stock Predictions, Articles, and CRISPR Therapeutics AG - Common Shares News
3 Gene Editing Stocks Shaping the Future of Medicine
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions
3 Gene Editing Stocks That Could Grow Your Wealth
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks.
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders.
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future.
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge
3 Top-Rated Gene Editing Stocks Actually Making Money
Profitable gene editing stocks make increasingly compelling investments as therapies commercialize this year and beyond.
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects.
Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich
These three biotech stocks to buy carry risks but may appeal to speculative investors with time and patience.
You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Invest in the top biotech stocks to buy, as the sector pivots from pandemic-driven vaccine sales to solutions for chronic conditions.
3 Biotech Stocks That Could Make Your Grandchildren Rich
These biotech stocks are poised to generate significant returns to investors due to their high growth potential.
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks.
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions.
The Next Big Thing After AI? 3 Sleeper Stocks to Buy Before the Boom
These three sleeper stocks could deliver massive gains if their cutting-edge technologies take off in the coming years.
